352 related articles for article (PubMed ID: 22542493)
21. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells.
Bianco C; Adkins HB; Wechselberger C; Seno M; Normanno N; De Luca A; Sun Y; Khan N; Kenney N; Ebert A; Williams KP; Sanicola M; Salomon DS
Mol Cell Biol; 2002 Apr; 22(8):2586-97. PubMed ID: 11909953
[TBL] [Abstract][Full Text] [Related]
22. Cripto-1 promotes epithelial-mesenchymal transition in prostate cancer via Wnt/β-catenin signaling.
Liu Y; Qin Z; Yang K; Liu R; Xu Y
Oncol Rep; 2017 Mar; 37(3):1521-1528. PubMed ID: 28098905
[TBL] [Abstract][Full Text] [Related]
23. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
24. ErbB/EGF signaling and EMT in mammary development and breast cancer.
Hardy KM; Booth BW; Hendrix MJ; Salomon DS; Strizzi L
J Mammary Gland Biol Neoplasia; 2010 Jun; 15(2):191-9. PubMed ID: 20369376
[TBL] [Abstract][Full Text] [Related]
25. Cripto monoclonal antibodies.
Hu XF; Xing PX
Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
[TBL] [Abstract][Full Text] [Related]
26. Cripto as a target for cancer immunotherapy.
Hu XF; Xing PX
Expert Opin Ther Targets; 2005 Apr; 9(2):383-94. PubMed ID: 15934922
[TBL] [Abstract][Full Text] [Related]
27. Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling.
Gray PC; Shani G; Aung K; Kelber J; Vale W
Mol Cell Biol; 2006 Dec; 26(24):9268-78. PubMed ID: 17030617
[TBL] [Abstract][Full Text] [Related]
28. Cripto-1: an oncofetal gene with many faces.
Bianco C; Strizzi L; Normanno N; Khan N; Salomon DS
Curr Top Dev Biol; 2005; 67():85-133. PubMed ID: 15949532
[TBL] [Abstract][Full Text] [Related]
29. Cripto-1 as a novel therapeutic target for triple negative breast cancer.
Castro NP; Fedorova-Abrams ND; Merchant AS; Rangel MC; Nagaoka T; Karasawa H; Klauzinska M; Hewitt SM; Biswas K; Sharan SK; Salomon DS
Oncotarget; 2015 May; 6(14):11910-29. PubMed ID: 26059540
[TBL] [Abstract][Full Text] [Related]
30. Netrin-1 can affect morphogenesis and differentiation of the mouse mammary gland.
Strizzi L; Mancino M; Bianco C; Raafat A; Gonzales M; Booth BW; Watanabe K; Nagaoka T; Mack DL; Howard B; Callahan R; Smith GH; Salomon DS
J Cell Physiol; 2008 Sep; 216(3):824-34. PubMed ID: 18425773
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.
Wendt MK; Smith JA; Schiemann WP
Oncogene; 2010 Dec; 29(49):6485-98. PubMed ID: 20802523
[TBL] [Abstract][Full Text] [Related]
32. The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma.
Yoon HJ; Hong JS; Shin WJ; Lee YJ; Hong KO; Lee JI; Hong SP; Hong SD
Oral Oncol; 2011 Nov; 47(11):1023-31. PubMed ID: 21824804
[TBL] [Abstract][Full Text] [Related]
33. Role of the EGF-CFC gene cripto in cell differentiation and embryo development.
Minchiotti G; Parisi S; Liguori GL; D'Andrea D; Persico MG
Gene; 2002 Apr; 287(1-2):33-7. PubMed ID: 11992720
[TBL] [Abstract][Full Text] [Related]
34. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells.
Taylor MA; Parvani JG; Schiemann WP
J Mammary Gland Biol Neoplasia; 2010 Jun; 15(2):169-90. PubMed ID: 20467795
[TBL] [Abstract][Full Text] [Related]
35. Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-κB/survivin signaling pathway.
Zhang Y; Mi X; Song Z; Li Y; YingShi ; Niu J
Biomed Pharmacother; 2018 Aug; 104():729-737. PubMed ID: 29807222
[TBL] [Abstract][Full Text] [Related]
36. Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia.
Salomon DS; Bianco C; De Santis M
Bioessays; 1999 Jan; 21(1):61-70. PubMed ID: 10070255
[TBL] [Abstract][Full Text] [Related]
37. Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers.
Sandomenico A; Ruvo M
Curr Med Chem; 2019; 26(11):1994-2050. PubMed ID: 30207211
[TBL] [Abstract][Full Text] [Related]
38. Cripto-1: an extracellular protein - connecting the sequestered biological dots.
Klauzinska M; Bertolette D; Tippireddy S; Strizzi L; Gray PC; Gonzales M; Duroux M; Ruvo M; Wechselberger C; Castro NP; Rangel MC; Focà A; Sandomenico A; Hendrix MJ; Salomon D; Cuttitta F
Connect Tissue Res; 2015; 56(5):364-80. PubMed ID: 26327334
[TBL] [Abstract][Full Text] [Related]
39. Exogenous Cripto-1 Suppresses Self-Renewal of Cancer Stem Cell Model.
Alam MJ; Takahashi R; Afify SM; Oo AKK; Kumon K; Nawara HM; Khayrani AC; Du J; Zahra MH; Seno A; Salomon DS; Seno M
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373174
[TBL] [Abstract][Full Text] [Related]
40. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
